BETHESDA, Md., Feb. 10, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that Dr. Claire Kruger, Chief Executive Officer, will present to investors as part of the LHA, Inc. Life Sciences & Medical Technologies Virtual Conference on Thursday, February 16, 2012, at 12:30 p.m. Eastern time.
The webcast of the Spherix presentation will be accessible live and for 30 days at www.spherix.com or the PrecisionIR event site http://www.investorcalendar.com/IC/CEPage.asp?ID=167333.
This virtual conference event includes 30-minute presentations with accompanying slides from eight industry leaders, and begins at 9:00 a.m. Eastern time.
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis. Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived f
|SOURCE Spherix Incorporated|
Copyright©2010 PR Newswire.
All rights reserved